Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)
Baird Equity Asset Management recently released its "Small/Mid Cap Growth Strategy" second-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Alkermes Plc. (ALKS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 433,263 | $17,555,816 | +4% | 0.01% |
| 2. | Antipodes Partners Jacob Mitchell | 890 | $36,063 | 0% | |
| 3. | Bailard Inc Thomas Bailard | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.31 | 35,000 | $815,734.50 | 80,000 | 2022-11-14 | Filing | |
| $23.43 | 427 | $10,004.61 | 9,366 | 2022-03-04 | Filing | |
| $30.22 | 1,650 | $49,860.40 | 1,650 | 2021-08-23 | Filing | |
| $26.43 | 10,000 | $264,269.00 | 10,000 | 2021-08-02 | Filing | |
| $19.65 | 6,940 | $136,371.00 | 11,242 | 2020-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.17 | 2,035 | $93,955.95 | 219,353 | 2026-11-03 | Filing | |
| $41.03 | 2,034 | $83,455.02 | 221,388 | 2026-10-02 | Filing | |
| $48.01 | 2,034 | $97,652.34 | 223,422 | 2026-09-03 | Filing | |
| $46.99 | 9,000 | $422,874.00 | 65,389 | 2026-09-01 | Filing | |
| $49.65 | 664 | $32,969.33 | 102,193 | 2026-08-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,151,427 | $127,699,823 | 0.02% | |
| 2. | 1,102,990 | $44,693,155 | 0.02% | |
| 3. | 1,089,372 | $44,141,350 | 0.01% | |
| 4. | 1,009,318 | $41,012,479 | 0.04% | |
| 5. | 350,438 | $14,367,958 | 0.07% |
News See All
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD).
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?
It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report.
Alkermes plc (NASDAQ:ALKS) Q1 2026 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q1 2026 Earnings Call Transcript May 5, 2026Alkermes plc beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.57.
10 Stocks Dominating Today's Market Surge: ImmunityBio, Alkermes, and More
Ten stocks soared by double digits on Tuesday, outperforming Wall Street, as investors took heart from a flurry of corporate and industry developments, including acquisition deals.
Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript February 25, 2026Alkermes plc misses on earnings expectations. Reported EPS is $0.2924 EPS, expectations were $0.43.
Jim Cramer Recently Looked at These 25 Stocks
Jim Cramer, the host of Mad Money, on Friday commented on the ongoing chip shortages and also discussed Micron’s decision to break ground on a domestic chip manufacturing facility.
Why Analysts are Rating Alkermes (ALKS) a Buy
Alkermes plc (NASDAQ:ALKS) is one of the most promising mid-cap healthcare stocks under $50. At the close of play on December 19, the consensus ratings remain bullish for Alkermes plc (NASDAQ:ALKS).
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment
Alkermes Plc (NASDAQ:ALKS) is one of the best breakout stocks to invest in.
Hedge Fund Resource Center